Fidson Healthcare (FIDSON.NL) Stock Price

Fidson Healthcare Plc manufactures and distributes pharmaceutical products, including drugs, infusion and injectables, across its segments: over-the-counter, ethical products, and consumer. The over-the-counter segment sells products directly to consumers without prescriptions, while the ethical products segment offers prescription-only drugs, injectables, and infusions. The consumer segment focuses on household items. The company provides formulation/development, contract manufacturing, and production services for medicines. Its product portfolio includes Anti Infective & Anti Malaria, Central Nervous System (CNS), Gastrointestinal Medicines, Supplements, Topical/Dermatological Medicines, Vitamins & Minerals, Ophthalmic Solution, and others, with Ophthalmic Solution specifically targeting eye conditions. The company's primary revenue streams come from the sale of pharmaceutical products within its three segments. Over-the-counter products are purchased by general consumers, ethical products are bought by healthcare providers and pharmacies requiring prescriptions, and consumer segment items are sold to households. Fidson Healthcare Plc serves the Nigerian market through its manufacturing and distribution network, leveraging its full-time workforce of 593 employees to support operations. Fidson Healthcare Plc's product lines are tailored to specific market needs, with Anti Infective & Anti Malaria products addressing infectious diseases, CNS medications targeting neurological disorders, and Ophthalmic Solution treating eye conditions. The company's services in formulation/development and contract manufacturing further generate revenue by supporting other pharmaceutical firms in product creation and production.